Read More

Rain Oncology Provides Company Update And Outlines Strategic Priorities Of Milademetan Clinical Programs; Workforce Reduction Of ~65% Of The Company’s Employees; With A Transition Of Chief Medical Officer Responsibilities

– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and terminate plans for its Phase 1/2 MANTRA-4 combination trial –   – Evaluation of outcomes from

RAIN

Read More

Seatankers Group Delivers Open Letter To Fellow Shareholders Of International Seaways, Inc.; Believes That The Board Suffers From Various Governance Shortcomings And Requires Significant Corporate Governance Reform And Refreshment

Expresses Frustration with the Board's Refusal to Meaningfully Engage with the Seatankers Group on Shareholder Value-Creation   Believes that the Board Suffers from Various Governance Shortcomings and Requires

INSW